SEC Form 4 · accession 0001628280-26-051087
Ginkgo Bioworks Holdings, Inc. · DNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Reshma P. Shetty
Officer — See remarks · Director · 10% Owner
Period of report
Jul 28, 2026
Accepted (ET)
Jul 30, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001830214
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 28, 2026 | A | 39,038 | A | — | — | Class A Common Stock | 39,038 | 39,038 | D |
| Restricted Stock UnitsF1,F3 | — | Jul 28, 2026 | A | 127,423 | A | — | — | Class A Common Stock | 127,423 | 127,423 | D |
| Restricted Stock UnitsF1,F2 | — | Jul 28, 2026 | A | 35,736 | A | — | — | Class A Common Stock | 35,736 | 35,736 | I |
| Restricted Stock UnitsF1,F3 | — | Jul 28, 2026 | A | 117,135 | A | — | — | Class A Common Stock | 117,135 | 117,135 | I |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F2The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
- F3The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
Remarks
President & Founder